Dr. Campbell, a nurse and educator, retired from the NIH in the UK, brought up some data from a study on the incidence of cerebral blood clots in various circumstances and compared it to publicly available data on the incidence of blood clots concerning the J&J COVID vaccine.
From the data presented, it would be enough to compare the incidence of cerebral clots with contracting COVID itself, or even influenza, to realize that the caution being taken in the pause on the J&J vaccine is overly abundant. But, when compared to the incidence of clots with the Pfizer and Moderna shots, it looks as if there’s more of a problem with the CDC and FDA than there is with the vaccine.
Apparently, word about this data has gotten around, because in just the last 12 hours or so, the reason for the pause floating around in the media is that they also wanted to look at the strong side effects that have been reported. While I am aware that, just prior to the pause, some vaccination sites that were distributing the J&J vaccine had been shut after a handful of individuals became sicker than expected, the company had said that these symptoms were expected and normal.
It probably goes without saying that this pause has an opportunity cost in terms of people not getting shots that otherwise would have, but also in terms of credibility of the shots in general that sort of bends around back to the first point. And, of course, it has an economic cost as well, for however long the pause or whatever restrictions are placed on the vaccine adds to the length of the pandemic and its adverse economic impacts.
Whatever the issue is, I certainly hope it can pass cost/benefit analysis.
The data discussion starts at 23:15 on the video below.